Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Goodwill & Intangibles (2016 - 2023)

Sangamo Therapeutics (SGMO) has 11 years of Goodwill & Intangibles data on record, last reported at $51.6 million in Q1 2023.

  • For Q1 2023, Goodwill & Intangibles fell 43.73% year-over-year to $51.6 million; the TTM value through Mar 2023 reached $51.6 million, down 43.73%, while the annual FY2022 figure was $88.3 million, 5.54% down from the prior year.
  • Goodwill & Intangibles reached $51.6 million in Q1 2023 per SGMO's latest filing, down from $88.3 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $100.9 million in Q4 2020 and bottomed at $51.6 million in Q1 2023.
  • Average Goodwill & Intangibles over 5 years is $83.2 million, with a median of $91.6 million recorded in 2022.
  • Peak YoY movement for Goodwill & Intangibles: skyrocketed 3300.13% in 2019, then tumbled 43.73% in 2023.
  • A 5-year view of Goodwill & Intangibles shows it stood at $92.4 million in 2019, then rose by 9.19% to $100.9 million in 2020, then fell by 7.4% to $93.5 million in 2021, then fell by 5.54% to $88.3 million in 2022, then tumbled by 41.6% to $51.6 million in 2023.
  • Per Business Quant database, its latest 3 readings for Goodwill & Intangibles were $51.6 million in Q1 2023, $88.3 million in Q4 2022, and $81.0 million in Q3 2022.